npj Breast Cancer (Jan 2022)
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
- Sherene Loi,
- Roberto Salgado,
- Sylvia Adams,
- Giancarlo Pruneri,
- Prudence A. Francis,
- Magali Lacroix-Triki,
- Heikki Joensuu,
- Maria Vittoria Dieci,
- Sunil Badve,
- Sandra Demaria,
- Robert Gray,
- Elisabetta Munzone,
- Damien Drubay,
- Jerome Lemonnier,
- Christos Sotiriou,
- Pirkko Liisa Kellokumpu-Lehtinen,
- Andrea Vingiani,
- Kathryn Gray,
- Fabrice André,
- Carsten Denkert,
- Martine Piccart,
- Elvire Roblin,
- Stefan Michiels
Affiliations
- Sherene Loi
- Peter MacCallum Cancer Centre
- Roberto Salgado
- Peter MacCallum Cancer Centre
- Sylvia Adams
- New York University Langone Health, Perlmutter Cancer Center
- Giancarlo Pruneri
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico-Isituto Nazionale dei Tumori, Universita degli Studi di Milano
- Prudence A. Francis
- Peter MacCallum Cancer Centre
- Magali Lacroix-Triki
- Gustave Roussy, Université Paris-Saclay
- Heikki Joensuu
- Helsinki University Hospital and University of Helsinki
- Maria Vittoria Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padua
- Sunil Badve
- Indiana University
- Sandra Demaria
- Weill-Cornell Medicine
- Robert Gray
- Dana-Farber Cancer Institute
- Elisabetta Munzone
- Division of Medical Senology, European Institute of Oncology, IRCCS
- Damien Drubay
- Service de Biostatistique et d’Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer
- Jerome Lemonnier
- R&D UNICANCER
- Christos Sotiriou
- Institut Jules Bordet, Universite Libre de Bruxelles
- Pirkko Liisa Kellokumpu-Lehtinen
- Faculty of Medicine and Health Technology Tampere University and Tampere University Hospital Tamper
- Andrea Vingiani
- Fondazione Istituto di Ricovero e Cura a Carattere Scientifico-Isituto Nazionale dei Tumori, Universita degli Studi di Milano
- Kathryn Gray
- Frontier Science & Technology Research Foundation
- Fabrice André
- Gustave Roussy, Université Paris-Saclay
- Carsten Denkert
- Institut für Pathologie, Universitätsklinikum Marburg, Philipps-Universität Marburg
- Martine Piccart
- Institut Jules Bordet, Universite Libre de Bruxelles
- Elvire Roblin
- Service de Biostatistique et d’Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer
- Stefan Michiels
- Service de Biostatistique et d’Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer
- DOI
- https://doi.org/10.1038/s41523-021-00362-1
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 4
Abstract
Abstract The importance of integrating biomarkers into the TNM staging has been emphasized in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging system. In a pooled analysis of 2148 TNBC-patients in the adjuvant setting, TILs are found to strongly up and downstage traditional pathological-staging in the Pathological and Clinical Prognostic Stage Groups from the AJJC 8th edition Cancer Staging System. This suggest that clinical and research studies on TNBC should take TILs into account in addition to stage, as for example patients with stage II TNBC and high TILs have a better outcome than patients with stage I and low TILs.
